Share |
News

Canadian Cancer Society names Verisante Core a Top 10 Cancer Breakthrough of 2011


January 9, 2012 at 9:45 am

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that a research study using its Laser Raman Spectroscopy was named as one of the Canadian Cancer Society’s
10 research achievements for 2011. 

"2011 has been a very exciting year for cancer research," said the Canadian Cancer Society’s Sarah Bouma. "Society funded researchers have made tremendous gains, particularly in clinical trials. Research advances across the country are impacting the lives of people living with cancer, their families and caregivers."

In July 2011, Verisante announced the results of a pilot study on lung cancer detection led by Dr. Stephen Lam and Dr. Haishan Zeng and conducted at the Lung Centre at Vancouver General Hospital.  Results were published in the Journal of Thoracic Oncology.  The study, funded by the Canadian Cancer Society, used the Verisante Core’s Laser Raman Spectroscopy System, which was able to detect pre-cancerous lung lesions with 96 percent sensitivity and 91 percent specificity when used in combination with existing methods.  The application of the Core could improve early detection of lung cancer and reduce the number of false positives associated with other methods.

The Canadian Cancer Society’s recognition comes soon after editors of Popular Science magazine named Verisante’s Aura™ device for skin cancer detection as a top technology innovation of 2011, receiving one of the magazine’s coveted “Best of What’s New” Awards.

 “The recent accolades from the Society and Popular Science for Verisante technologies reflects our commitment to helping healthcare providers save lives through the early detection of some of the common forms of cancer,” said Thomas Braun, Verisante President and CEO. 

For further information, please see the Canadian Cancer Society’s media release and Top 10 Breakthrough fact sheet.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver
 
General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers.   The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.


The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:
                       
Thomas Braun, President & CEO                   
Verisante Technology, Inc.                   
Telephone: (604) 605-0507                   
Email: info@verisante.com                   
Website:  www.verisante.com                     
Youtube:  www.youtube.com/verisante                 
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top